Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REC 0482
- Development stage
- Discontinued
- Lead developer
- Recordati Rare Diseases
- Modality
- Small Molecules
- Administration
- Intraprostatic
01
Overview
REC 0482 (also known as NX-1207) is an innovative small molecule developed for the treatment of benign prostatic hyperplasia (BPH). It is administered via a single transrectal ultrasound (TRUS)-guided intraprostatic injection to patients with lower urinary tract symptoms (LUTS) associated with BPH who are not adequately controlled by medical therapy. The drug was being prepared for a pivotal European Phase III clinical trial following a successful Scientific Advice meeting with the European Medicines Agency (EMA), with activities initiated in early 2012 by Recordati S.p.A.[2]
Beyond the preview
Go deeper on REC 0482.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REC 0482.